|Eli Lilly CEO John Lechleiter|
14. Eli Lilly ($LLY)
2014 revenue: $19.615 billion
2013 revenue: $23.113 billion
Eli Lilly--number 10 on FiercePharma's 2013 list of pharma companies--fell out of the top 10 in 2014 thanks to sagging sales of antidepressant Cymbalta and osteoporosis drug Evista following patent expirations.
On the year, the Indianapolis-based pharma company saw revenue fall to $19.6 billion, a 15% drop from its 2013 total of $23.1 billion. Cymbalta sales fell 68% on the year from $5.1 billion to $1.6 billion and, similarly, Evista sales fell from just over $1 billion to $419 million, a 60% drop.
"While Lilly's fourth-quarter 2014 results continue to reflect the impact of patent expirations, we are moving to a period of growth led by diabetes, oncology and animal health," said CEO John C. Lechleiter. "Despite the loss of significant revenue for Cymbalta and Evista following the expiration of our U.S. patents, we saw strong performance from many other products. At the same time, we made excellent progress with our innovation-based strategy, and we continue to advance our pipeline."
Earnings per share on the year fell 33% from $4.15 to $2.78.
In 2015, the company hopes to move past its self-described "trough year," and will look to grab market share for Trulicity and Jardiance in a crowded diabetes space. Cyramza also presents an opportunity, but work will be needed to help it gain share against immuno-oncology meds such as Merck's ($MRK) Keytruda.
"Throughout the balance of this decade, we aim to drive revenue growth and expand margins as we offer new medicines to the people who need them," Lechleiter said in the company's fourth quarter earnings release.
For its 2015 guidance, the drugmaker predicted mid to high single-digit percentage growth in sales, before factoring in generic erosion and currency factors. Coming in lower than analyst expectations, Lilly expects revenue of $20.3 billion to $20.8 billion and earnings of $2.40 to $2.50 per share.
"In the end, 2015 is a year of execution, and perhaps not 'transformation,' for [Lilly]," Evercore/ISI Group analyst Mark Schoenebaum wrote in an investor note. "2016, however, gets far more interesting."
-- Eric Sagonowsky (email)
Lilly's sales and earnings continue their free-fall but CEO Lechleiter sees good things coming
Lilly leans on diabetes, Cyramza in predictions for 2015 growth
Eli Lilly continues downward spiral in Q3 as generics slam Cymbalta, Evista sales
Eli Lilly's Q2 profit sags on patent expirations but beats (low) expectations
Lilly warns of challenging bid for 2014 sales goal, thanks to yen, emerging markets
A 'not great' quarter for Eli Lilly, but then everyone expected that